Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER
LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was an FDA-mandated cardiovascular outcome trial with liraglutide and was the first trial with a glucagon-like peptide-1 (GLP-1) receptor agonist to demonstrate a significant reduction in cardiovascular...
Gespeichert in:
Veröffentlicht in: | British Journal of Diabetes 2020-12, Vol.20 (2), p.142-144 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 144 |
---|---|
container_issue | 2 |
container_start_page | 142 |
container_title | British Journal of Diabetes |
container_volume | 20 |
creator | Fisher, Miles |
description | LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was an FDA-mandated cardiovascular outcome trial with liraglutide and was the first trial with a glucagon-like peptide-1 (GLP-1) receptor agonist to demonstrate a significant reduction in cardiovascular events. It compared liraglutide and placebo in 9,340 people with type 2 diabetes and either existing cardiovascular disease or age >60 years with at least one cardiovascular risk factor. LEADER demonstrated superiority for major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), and cardiovascular deaths were significantly reduced, as was all-cause mortality. Hospitalisation for heart failure, which was a secondary outcome, was not significantly reduced. Compared with the EMPA-REG OUTCOME trial, the curves for major adverse cardiovascular events in LEADER separated later, and the absence of a clear effect on hospitalisation for heart failure or on estimated glomerular filtration rate suggests that the mechanism of cardiovascular benefit for liraglutide was different from that for empagliflozin |
doi_str_mv | 10.15277/bjd.2020.267 |
format | Article |
fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_15277_bjd_2020_267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_15277_bjd_2020_267</sourcerecordid><originalsourceid>FETCH-LOGICAL-c123t-d1423e86b6aa6cdfec9a8020000223a19d301523ed9c3df9ccbd0bc37dd42103</originalsourceid><addsrcrecordid>eNo9kM1OwzAQhC0EElXpkbtfIMHeDU7DrQqFIkWqBL1bttepjFKC7ASJt8f8iLnMXGa0-zF2LUUpb6Gub-wrlSBAlKDqM7YAbOpCQSXP_zPiJVulFKwAJWStUCzY_sXH4NMdb02kMH6Y5ObBRD7OkxtPnk8xmCHxfoycgrF-8olTnI-JdyGa4zBPgTw3b8S77eZ--3zFLvpc8Ks_X7LDw_bQ7opu__jUbrrCScCpIFkB-rWyyhjlqPeuMet8fBYAGtkQivwWemocUt84Z0lYhzVRBVLgkhW_sy6OKUXf6_cYTiZ-ain0Dw-deehvHjrzwC-g51O1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Fisher, Miles</creator><creatorcontrib>Fisher, Miles</creatorcontrib><description>LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was an FDA-mandated cardiovascular outcome trial with liraglutide and was the first trial with a glucagon-like peptide-1 (GLP-1) receptor agonist to demonstrate a significant reduction in cardiovascular events. It compared liraglutide and placebo in 9,340 people with type 2 diabetes and either existing cardiovascular disease or age >60 years with at least one cardiovascular risk factor. LEADER demonstrated superiority for major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), and cardiovascular deaths were significantly reduced, as was all-cause mortality. Hospitalisation for heart failure, which was a secondary outcome, was not significantly reduced. Compared with the EMPA-REG OUTCOME trial, the curves for major adverse cardiovascular events in LEADER separated later, and the absence of a clear effect on hospitalisation for heart failure or on estimated glomerular filtration rate suggests that the mechanism of cardiovascular benefit for liraglutide was different from that for empagliflozin</description><identifier>ISSN: 2397-6233</identifier><identifier>EISSN: 2397-6241</identifier><identifier>DOI: 10.15277/bjd.2020.267</identifier><language>eng</language><ispartof>British Journal of Diabetes, 2020-12, Vol.20 (2), p.142-144</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Fisher, Miles</creatorcontrib><title>Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER</title><title>British Journal of Diabetes</title><description>LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was an FDA-mandated cardiovascular outcome trial with liraglutide and was the first trial with a glucagon-like peptide-1 (GLP-1) receptor agonist to demonstrate a significant reduction in cardiovascular events. It compared liraglutide and placebo in 9,340 people with type 2 diabetes and either existing cardiovascular disease or age >60 years with at least one cardiovascular risk factor. LEADER demonstrated superiority for major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), and cardiovascular deaths were significantly reduced, as was all-cause mortality. Hospitalisation for heart failure, which was a secondary outcome, was not significantly reduced. Compared with the EMPA-REG OUTCOME trial, the curves for major adverse cardiovascular events in LEADER separated later, and the absence of a clear effect on hospitalisation for heart failure or on estimated glomerular filtration rate suggests that the mechanism of cardiovascular benefit for liraglutide was different from that for empagliflozin</description><issn>2397-6233</issn><issn>2397-6241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kM1OwzAQhC0EElXpkbtfIMHeDU7DrQqFIkWqBL1bttepjFKC7ASJt8f8iLnMXGa0-zF2LUUpb6Gub-wrlSBAlKDqM7YAbOpCQSXP_zPiJVulFKwAJWStUCzY_sXH4NMdb02kMH6Y5ObBRD7OkxtPnk8xmCHxfoycgrF-8olTnI-JdyGa4zBPgTw3b8S77eZ--3zFLvpc8Ks_X7LDw_bQ7opu__jUbrrCScCpIFkB-rWyyhjlqPeuMet8fBYAGtkQivwWemocUt84Z0lYhzVRBVLgkhW_sy6OKUXf6_cYTiZ-ain0Dw-deehvHjrzwC-g51O1</recordid><startdate>20201213</startdate><enddate>20201213</enddate><creator>Fisher, Miles</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20201213</creationdate><title>Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER</title><author>Fisher, Miles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c123t-d1423e86b6aa6cdfec9a8020000223a19d301523ed9c3df9ccbd0bc37dd42103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fisher, Miles</creatorcontrib><collection>CrossRef</collection><jtitle>British Journal of Diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fisher, Miles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER</atitle><jtitle>British Journal of Diabetes</jtitle><date>2020-12-13</date><risdate>2020</risdate><volume>20</volume><issue>2</issue><spage>142</spage><epage>144</epage><pages>142-144</pages><issn>2397-6233</issn><eissn>2397-6241</eissn><abstract>LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was an FDA-mandated cardiovascular outcome trial with liraglutide and was the first trial with a glucagon-like peptide-1 (GLP-1) receptor agonist to demonstrate a significant reduction in cardiovascular events. It compared liraglutide and placebo in 9,340 people with type 2 diabetes and either existing cardiovascular disease or age >60 years with at least one cardiovascular risk factor. LEADER demonstrated superiority for major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), and cardiovascular deaths were significantly reduced, as was all-cause mortality. Hospitalisation for heart failure, which was a secondary outcome, was not significantly reduced. Compared with the EMPA-REG OUTCOME trial, the curves for major adverse cardiovascular events in LEADER separated later, and the absence of a clear effect on hospitalisation for heart failure or on estimated glomerular filtration rate suggests that the mechanism of cardiovascular benefit for liraglutide was different from that for empagliflozin</abstract><doi>10.15277/bjd.2020.267</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2397-6233 |
ispartof | British Journal of Diabetes, 2020-12, Vol.20 (2), p.142-144 |
issn | 2397-6233 2397-6241 |
language | eng |
recordid | cdi_crossref_primary_10_15277_bjd_2020_267 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
title | Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T10%3A52%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Series:%20Cardiovascular%20outcome%20trials%20for%20diabetes%20drugs%20Liraglutide%20and%20LEADER&rft.jtitle=British%20Journal%20of%20Diabetes&rft.au=Fisher,%20Miles&rft.date=2020-12-13&rft.volume=20&rft.issue=2&rft.spage=142&rft.epage=144&rft.pages=142-144&rft.issn=2397-6233&rft.eissn=2397-6241&rft_id=info:doi/10.15277/bjd.2020.267&rft_dat=%3Ccrossref%3E10_15277_bjd_2020_267%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |